帕米帕利作为局限期小细胞肺癌同步放化疗后巩固治疗的单臂开放标签2期试验
该单臂开放标签2期试验拟入组18-75岁、经组织学/细胞学确诊的局限期小细胞肺癌患者,在完成含铂同步放化疗后未进展且ECOG PS 0-1者接受帕米帕利40 mg每日两次、每3周为一周期,于cCRT后2-6周内开始,最长1年或至RECIST v1.1疾病进展;主要终点为研究者按RECIST v1.1评估的1年无进展生存率,次要终点包括PFS、客观缓解率、缓解持续时间、总生存、远处转移时间及安全性。
要点
- 帕米帕利为口服高选择性PARP1/2抑制剂,具强PARP捕获活性和良好脑穿透性。
- 入组标准为局限期SCLC、含铂cCRT后未进展、ECOG PS 0或1、年龄18-75岁。
- 主要终点为研究者按RECIST v1.1评估的1年无进展生存率,帕米帕利40 mg每日两次给药。
核心结论
- 该研究将为帕米帕利作为局限期小细胞肺癌同步放化疗后巩固治疗的可行性、安全性和有效性提供数据。
- 将进一步探索疾病的分子分型或基因表达谱与疗效之间的相关性。
研究设计与样本
- 单臂、开放标签2期试验,拟入组18-75岁经组织学/细胞学确诊的局限期小细胞肺癌患者。
- 患者须在含铂同步放化疗后未进展且ECOG PS为0或1。
- 排除组织学确诊的混合型SCLC或NSCLC、既往接受过肿瘤切除、或可接受手术或立体定向体部放疗/立体定向消融放疗者。
- 帕米帕利40 mg每日两次、每3周为一周期,于cCRT后2至6周内开始,最长1年或至RECIST v1.1疾病进展。
- 主要终点为研究者按RECIST v1.1评估的1年无进展生存率;次要终点包括PFS、客观缓解率、缓解持续时间、总生存、远处转移时间和安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Small cell lung cancer (SCLC) is highly invasive with poor prognosis, and its treatment has historically been hindered due to the absence of targetable driver genomic alterations. However, the high genomic instability and replication stress in SCLC have made poly(ADP-ribose) polymerases (PARPs) inhibitors a focus of research. Pamiparib is an orally available PARP1/2 inhibitor with high selectivity, strong PARP trapping activity, and excellent brain penetration. Utilizing pamiparib as consolidation maintenance therapy in limited-stage SCLC holds promise for improving survival outcomes and offering a viable therapeutic approach. METHODS: This single-arm, open-label phase II trial will enroll patients aged 18-75 years with histologically/cytologically confirmed, limited-stage SCLC who have not progressed following definitive platinum-based cCRT and have an ECOG PS of 0 or 1. Patients will be excluded if they have histologically confirmed mixed SCLC or NSCLC, or have undergone previous tumor resection, or can be treated with surgery or stereotactic body radiation therapy/stereotactic ablative radiation therapy. Participants will receive pamiparib 40 mg twice daily every 3 weeks within 2 to 6 weeks after cCRT for up to 1 year or until disease progression according to RECIST v1.1. The primary endpoint is the 1-year progression-free survival (PFS) rate assessed by investigators per RECIST v1.1. Secondary endpoints include PFS, objective response rate, and duration of response assessed by investigators per RECIST 1.1, overall survival, time to distant metastasis, and safety. DISCUSSION: The study will provide valuable data on the feasibility, safety, and effectiveness of pamiparib as a consolidation therapy after cCRT in patients with LS-SCLC. The correlation between molecular typing or gene expression profile of the disease and curative response will be further explored. TRIAL REGISTRATION: NCT05483543 at clinicaltrials.gov.
引用
- Mao J, Ni J, Chu L, et al. Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial. Radiat Oncol. 2024. PMID: 38610031. doi:10.1186/s13014-024-02437-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。